Total Funding
32
60
Total FundingSeries B raised
Growth Score 32 in past quarter
-42 pts
Heat Score 60 in past quarter
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
16533
Candesant Biomedical develops treatment for excessive sweating and hyperhidrosis.
- Niquette Hunt: President and CEOPast Role: Revance Therapeutics, Senior Vice President, Commercial Development
- Jesse Rosen: VP Product Development
About the Company
Candesant Biomedical develops treatment for excessive sweating and hyperhidrosis. It offers a technology that is based on the principle that alkali metals in contact with water generate energy. The insight was that when the amounts of metal and water are controlled, the result is targeted delivery of energy exactly at the site of the water. Its
device is designed to target and inactivate the most active sweat glands.
The company was founded in 2016 and is headquartered in San Francisco, California.
Women Founded
Women Led